The Approval Granted By The Us Food And Drug Administration (Usfda) Is To Market Triazolam Tablets Of Strengths 0.125 Mg And 0.25 Mg, The Company Said In A Regulatory Filing.Zydus Lifesciences Ltd On Friday Said It Has Received Final Approval From The Us Health Regulator To Market Its Generic Version Of Triazolam Tablets Used On A Short-Term Basis To Treat Insomnia. The Approval Granted By The Us Food And Drug Administration (Usfda) Is To Market Triazolam Tablets Of Strengths 0.125 Mg And 0.25 Mg, The Company Said In A Regulatory Filing. The Medicine Is Used On A Short-Term Basis To Treat Insomnia And Difficulty Falling Asleep Or Staying Asleep. It Works By Slowing Activity In The Brain To Allow Sleep. It Will Be Manufactured At The Group'S Formulation Manufacturing Facility At Moraiya.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!